Editas Medicine Reports Sale Of Certain Future License Fees, Other Payments Owed Under Cas9 License Agreement With Vertex To DRI Healthcare Trust Subsidiary For Upfront Cash Payment Of $57M
Editas Medicine Reports Sale Of Certain Future License Fees, Other Payments Owed Under Cas9 License Agreement With Vertex To DRI Healthcare Trust Subsidiary For Upfront Cash Payment Of $57M
The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities.
预付现金为Editas Medicine带来了非稀释性资本，有助于实现进一步的管道开发和相关的战略重点。
Under the terms of the agreement, Editas Medicine will receive an upfront cash payment of $57 million in exchange for up to 100% of certain future annual license fees payable to Editas Medicine, ranging from $5 million to $40 million per year (inclusive of certain sales-based annual license fees that may become due) and a mid-double-digit percentage of Editas Medicine's portion of a $50 million contingent upfront payment for which Editas Medicine is eligible under the Vertex license agreement.
根据协议条款，Editas Medicine将获得5700万美元的预付现金，以换取未来应付给Editas Medicine的某些年度许可费的100％，从每年500万美元到4000万美元不等（包括可能到期的某些基于销售的年度许可费），以及Editas Medicine在Vertex许可下有资格获得的5000万美元或有资格预付的部分中两位数的百分比协议。
In addition to a portion of any such contingent upfront payment, Editas Medicine retains rights to fixed annual license fees for 2024 and a mid-single-digit million-dollar payment due to Editas Medicine in the event of Vertex's achievement of certain annual sales milestones.
除了任何此类或有预付款的一部分，Editas Medicine保留获得2024年的固定年度许可费的权利，以及在Vertex实现某些年度销售里程碑时应向Editas Medicine支付的中等个位数百万美元的款项的权利。
